Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of drug therapy, direct current stimulation, and neurofeedback for insomnia and depression
IRCT20241015063379N1Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of melatonin in major depressive disorder (MDD) and Insomnia (4 arms), sponsored by Islamic Azad University. Primary endpoints: Sleep quality, Insomnia severity and 1 more. Started Nov 2024; status: completed.
02
Drugs
melatonin
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on IRCT20241015063379N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241015063379N1.